99m锝-L,L-乙二巯基丁二酸在慢性肾衰竭患者中的临床评估。

Clinical evaluation of technetium-99m-L,L-ethylenedicysteine in patients with chronic renal failure.

作者信息

Prvulovich E M, Bomanji J B, Waddington W A, Rudrasingham P, Verbruggen A M, Ell P J

机构信息

Institute of Nuclear Medicine, University College London Medical School, United Kingdom.

出版信息

J Nucl Med. 1997 May;38(5):809-14.

PMID:9170451

Abstract

UNLABELLED

Technetium-99m-L,L-ethylenedicysteine (99mTc-L,L-EC), a new renal radiopharmaceutical, has been shown to have similar excretion characteristics but a higher plasma clearance than 99mTc-mercaptoacetyltriglycine (99mTc-MAG3) in normal volunteers and patients with obstructive nephropathy. This study evaluated 99mTc-L,L-EC in patients with chronic renal failure.

METHODS

The clearance of 99mTc-L,L-EC was compared with that of 125l-hippuran in 26 patients with varying degrees of chronic renal impairment (serum creatine 168-1163 mumol/liter). All 26 patients also were imaged with 99mTc-L,L-EC (70-80 MBq). Fifteen patients had further imaging with 99mTc-MAG3 (100 MBq) the following day.

RESULTS

A subjective analysis of the 99mTc-L,L-EC images revealed that all were of acceptable quality regardless of creatinine level. In the 15 patients who were imaged with both 99mTc-L,L-EC and 99mTc-MAG3, general image quality and target-to-background ratios were similar. Time-activity curves and mean parenchymal transit times obtained with the two agents were almost identical. Plasma clearance values (mean +/- s.d.) of 99mTc-L,L-EC and 125l-hippuran were 81 +/- 68 ml/min and 114 +/- 104 ml/min, respectively. Mean 99mTc-L,L-EC clearance was 71% of the mean 125l-hippuran value.

CONCLUSION

Technetium-99m-L,L-EC provides equally high-quality images to 99mTc-MAG3 in patients with chronic renal failure. Technetium-99m-L,L-EC clearance more closely resembles that of hippuran than does 99mTc-MAG3 clearance. These features together with its ease of preparation make 99mTc-L,L-EC an attractive alternative to 99mTc-MAG3 in patients with chronic renal failure.

摘要

未标记

锝-99m-L,L-乙二胺二巯基丁二酸（99mTc-L,L-EC）是一种新型肾放射性药物，在正常志愿者和梗阻性肾病患者中，其排泄特征与锝-99m-巯基乙酰三甘氨酸（99mTc-MAG3）相似，但血浆清除率更高。本研究对慢性肾衰竭患者使用99mTc-L,L-EC进行了评估。

方法

比较了26例不同程度慢性肾功能损害（血清肌酐168 - 1163μmol/升）患者中99mTc-L,L-EC与125I-马尿酸的清除率。所有26例患者均接受了99mTc-L,L-EC（70 - 80MBq）显像。15例患者在次日进一步接受了99mTc-MAG3（100MBq）显像。

结果

对99mTc-L,L-EC图像的主观分析显示，无论肌酐水平如何，所有图像质量均可接受。在同时接受99mTc-L,L-EC和99mTc-MAG3显像的15例患者中，总体图像质量和靶本底比值相似。两种药物获得的时间-活性曲线和实质平均通过时间几乎相同。99mTc-L,L-EC和125I-马尿酸的血浆清除率值（均值±标准差）分别为81±68ml/分钟和114±104ml/分钟。平均而言，99mTc-L,L-EC清除率为125I-马尿酸均值的71%。